CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 90 target
Drug / intervention
Clinical Assessmentsother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07116070
NCT07116070N/ARecruitingMonitorUpdated 10mo ago · Completion was 5mo ago
Slow Enrollment
Monitor

Sarcopenia and Related Factors in Patients With Multiple Sclerosis

Selcuk University·observational·Posted Aug 11, 2025·Updated Aug 11, 2025

In Brief

An observational study evaluating Clinical Assessments for Multiple Sclerosis and Sarcopenia. Currently recruiting, targeting 90 participants across 1 site.

Signals

Enrolling slower than its timeline implies

Detailed Summary

Multiple Sclerosis (MS) is a chronic disease affecting the central nervous system, exhibiting autoimmune and neurodegenerative properties. Neurological deficits, mobility limitations, and decreased muscle strength are commonly observed in MS patients as the disease progresses. The literature indicates that low physical activity levels and neurological deficits in individuals with MS can lead to decreased muscle mass and functional losses. Sarcopenia is a condition characterized by decreased skeletal muscle mass and strength associated with aging and chronic diseases, and studies on the prevalence of sarcopenia in MS patients are limited. Recent studies have revealed a high prevalence of sarcopenia in MS patients, which can have negative effects on physical performance, quality of life, and disease progression. Low muscle mass in MS patients can accelerate the loss of motor function and increase the level of disability. Additionally, nutritional deficiencies and low protein intake seen in MS patients are among the factors that accelerate muscle loss. Studies examining the relationship between MS and sarcopenia in the literature emphasize the importance of early diagnosis and intervention to improve patients' quality of life and functional independence. Factors such as muscle strength, physical activity level, and nutritional status should be assessed to determine the risk of sarcopenia in MS patients. This study was designed to determine the prevalence of sarcopenia in patients with Multiple Sclerosis (MS) and to examine the relationship between sarcopenia and fatigue, disability level (EDSS), nutritional status, and physical activity level. In this context: * The prevalence of sarcopenia in MS patients will be determined, * The relationship between sarcopenia and muscle strength, physical performance, and body composition will be evaluated, * The effects of nutrition and physical activity on sarcopenia in MS patients will be investigated.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesTurkey (Türkiye)
Collaborators--

Timeline

N/ARecruitingOverdue
2026
First PostedAug 11, 2025
Enrollment StartJun 1, 2025
Primary CompletionJan 20, 2026
Study CompletionMar 20, 2026
TodayJul 1, 2026
Enrollment to primary: 8 monthsPosted 11 months ago

Interventions

Clinical Assessmentsother

Participants will undergo the following assessments: * Muscle strength: Handgrip strength test (using a digital dynamometer), * Muscle mass: Bioelectrical impedance analysis (BIA) or DXA, * Physical performance: 6-minute walk test, 5-repetition sit-to-stand test, * Fatigue: Modified Fatigue Impact Scale (MFIS), * Disability: EDSS, * Nutritional status: Mini Nutritional Assessment (MNA), * Physical activity: Godin Leisure-Time Exercise Questionnaire, * Quality of life: MSQoL-54.